( WAKEFIELD Mass.--(BUSINESS WIRE)--Jul ...)BusinessWeek Article Highlights Promising Breakthrough Treatment,for Advanced Coronary Artery Disease,Health

WAKEFIELD, Mass.--(BUSINESS WIRE)--Jul 6, 2007 - BusinessWeek today published an article discussing the race by pharmaceutical and biotechnology companies to be first to bring to market an effective angiogenesis treatment for cardiovascular disease. While angiogenesis therapies are being pursued by Sanofi-Aventis, Boston Scientific, Baxter, and Genzyme, among others, the article highlights a very promising new biological therapy for advanced coronary artery disease (CAD) patients, FGF-1, from CardioVascular BioTherapeutics Inc. (CVBT).

BusinessWeek cites The Bruckner Group's (BGI) study presenting the preliminary value proposition for FGF-1 use in advanced coronary artery disease patients. According to BGI's study, FGF-1 has the potential to reduce treatment costs of advanced CAD patients by 20% over a five-year period after treatment.

Here is a link to the article: www.businessweek.com/technology/content/jul2007/tc2007075_259598.htm

"It's exciting when a breakthrough treatment appears with the potential to transform how we treat patients with a serious and costly disease like coronary artery disease," said Michael Russo, Partner, The Bruckner Group. "Typically, breakthrough treatments add cost to the healthcare system. BGI's study indicates, however, that FGF-1 could actually reduce total treatment costs, by as much as 20% over five years. We are looking forward to gathering evidence from the ongoing clinical trials to conclusively prove these points," Russo said.

According to Daniel Montano, CEO of CardioVascular BioTherapeutics, "The Bruckner Group's ongoing development of FGF-1's value proposition has been critical to FGF-1's commercial development. BGI's findings are allowing CVBT to have meaningful discussions with payers and employers. We are telling them that not only is a clinical breakthrough on the horizon that has the potential to revolutionize treatment for coronary artery dise
'"/>

Page: 1 2
Related medicine technology :

1. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
2. Peer Reviewed Journal Article Indicates Repros Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer
3. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
4. Callisto Pharmaceuticals Announces Publication of Research Article on Atiprimod Preclinical Studies in Mantle Cell Lymphoma
5. Expert Opinion Highlights Avigens AV411 as Potential New Therapeutic for Neuropathic Pain and Opioid Withdrawal
6. Positive Clinical Results for DG041 Lead Product Development Highlights at deCODE R&D Event
7. Ambrilia Highlights Encouraging Data for its HIV Integrase Inhibitor Program and Recent Developments at Annual Meeting
8. July Issue of Journal of Antimicrobial Chemotherapy Highlights Study of Factive Tablets for Five-Day Treatment of Community-Acquired Pneumonia
9. Inovio Biomedical Highlights Enhanced DNA Vaccine Potency with Electroporation DNA Delivery Technology and New Devices at Gene Therapy Meeting
10. Presentations at 2007 European Stroke Congress Highlights New Direction for Viprinex (ancrod)
11. Data to be Presented at ASCO 2007 Highlights sanofi-aventis Commitment to Cancer Care and Research